表皮生长因子受体-酪氨酸激酶抑制剂靶向治疗联合全身化疗治疗Ⅳ期肺腺癌的临床疗效  

Clinical efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor targeted therapy combined with systemic chemotherapy in the treatment of stage Ⅳ lung adenocarcinoma

作　　者：王璟珂[1] 郑杨秀 郝帅 WANG Jingke;ZHENG Yangxiu;HAO Shuai(Department of Thoracic Surgery,the First Affiliated Hospital of He’nan University of Science and Technology,Luoyang 471000,He’nan,China)

机构地区：[1]河南科技大学第一附属医院胸外科,河南洛阳4710000

出　　处：《癌症进展》2022年第6期581-584,共4页Oncology Progress

摘　　要：目的探讨表皮生长因子受体(EGFR)-酪氨酸激酶抑制剂(TKI)靶向治疗联合全身化疗治疗Ⅳ期肺腺癌的临床疗效。方法根据治疗方案不同将102例肺腺癌患者分为观察组(n=54)和对照组(n=48),对照组患者给予全身化疗,观察组患者在全身化疗的基础上给予EGFR-TKI靶向治疗。比较两组患者的临床疗效、免疫球蛋白[免疫球蛋白A(IgA)、IgG、IgM]水平、T淋巴细胞亚群(包括CD3^(+)、CD4^(+)、CD8^(+),计算CD4^(+)/CD8^(+))水平、生活质量[世界卫生组织生活质量测定简表(WHOQOL-BREF)]、不良反应发生情况。结果观察组患者的治疗总有效率为75.93%,高于对照组患者的52.08%(P﹤0.05)。治疗后,对照组患者IgA、IgG、IgM水平均明显低于本组治疗前(P﹤0.01),观察组患者IgA、IgG、IgM水平均明显高于本组治疗前(P﹤0.01),且观察组患者IgA、IgG、IgM水平均明显高于对照组(P﹤0.01)。治疗后,观察组患者CD3^(+)、CD4^(+)水平和CD4^(+)/CD8^(+)均明显高于对照组(P﹤0.01),CD8^(+)水平明显低于对照组(P﹤0.01)。治疗后,两组患者WHOQOL-BREF量表各维度评分均高于本组治疗前(P﹤0.01),且观察组患者WHOQOL-BREF量表各维度评分均明显高于对照组(P﹤0.01)。两组患者的恶心呕吐、骨髓抑制、肝肾功能减退、脱发、皮疹发生率均无明显差异(P﹥0.05)。结论EGFR-TKI靶向治疗联合全身化疗对Ⅳ期肺腺癌患者的治疗效果较好,可抑制肿瘤细胞生长和增殖,增强免疫功能,提高生活质量,且不良反应发生率较低。Objective To investigate the clinical efficacy of epidermal growth factor receptor(EGFR)-tyrosine kinase inhibitor(TKI)targeted therapy for systemic chemotherapy in the treatment of stage IV lung adenocarcinoma.Method According to different treatment plans,102 patients with lung adenocarcinoma were divided into observation group(n=54)and control group(n=48).The patients in the control group were given systemic chemotherapy,and the patients in the observation group were given EGFR-TKI targeted therapy on the basis of systemic chemotherapy.The clinical efficacy,immunoglobulin[immunoglobulin A(IgA)、IgG、IgM]levels,T lymphocyte subsets(including CD3^(+),CD4^(+),CD8^(+),calculated CD4^(+)/CD8^(+))levels,quality of life[World Health Organization quality of life assessment instrument-brief version(WHOQOL-BREF)],and adverse reactions were compared between the two groups.Result The total effective rate of the observation group was 75.93%,which was significantly higher than 52.08%of the control group(P<0.05).After treatment,the levels of IgA,IgG and IgM decreased in control group(P<0.01),and increased in observation group(P<0.01),with higher levels in observation group than those in control group(P<0.01).After treatment,the CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the observation group were significantly higher than those in the control group(P<0.01),and CD8^(+)lower than that in the control group(P<0.01).After treatment,the dimensional scores of WHOQOL-BREF in both groups were higher than those before treatment(P<0.01),with higher scores in the observation group than those in the control group(P<0.01).There were no significant differences in the incidence of nausea and vomiting,bone marrow suppression,liver and kidney function hypofunction,hair loss and rash between the two groups(P>0.05).Conclusion EGFR-TKI targeted therapy combined systemic chemotherapy has good therapeutic effect in patients with stage IV lung adenocarcinoma,which can inhibit the growth and proliferation of tumors,immune function and quality of life wit

关 键 词：肺腺癌 表皮生长因子受体 酪氨酸激酶抑制剂 全身化疗 

分 类 号：R734.2[医药卫生—肿瘤]